BeOne Medicines Ltd
282 hedge funds and large institutions have $9.95B invested in BeOne Medicines Ltd in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 124 increasing their positions, 68 reducing their positions, and 41 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 68
36% more call options, than puts
Call options by funds: $31.5M | Put options by funds: $23.1M
12% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 41
0.14% more ownership
Funds ownership: 31.73% → 31.87% (+0.14%)
0% more funds holding
Funds holding: 282 → 282 (0)
4% less capital invested
Capital invested by funds: $10.3B → $9.95B (-$400M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$185M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$116M |
| 3 |
Millennium Management
New York
|
+$99.7M |
| 4 |
Two Sigma Investments
New York
|
+$74.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$64.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$358M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$307M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$46.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$35.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$20.5M |
ONC Hedge Fund Activity: Q2 2026 in Review
282 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2026, worth a combined $9.95B — down 3.9% from $10.3B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ONC positions and 41 closed out — a net gain of 5 holders — while 124 added to existing stakes and 68 trimmed.
The largest buyer was Capital World Investors, adding an estimated $185M. The largest seller was Fidelity Investments, cutting an estimated $358M.
- 282 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $9.95B of BeOne Medicines Ltd stock for Q2 2026, down 3.9% quarter-over-quarter.
- 46 funds opened new BeOne Medicines Ltd positions in Q2 2026 and 41 closed out, a net change of +5 holders.
- The largest BeOne Medicines Ltd buyer in Q2 2026 was Capital World Investors, an estimated $185M added.
- The largest BeOne Medicines Ltd seller in Q2 2026 was Fidelity Investments, an estimated $358M sold.
Based on aggregated 13F filings for Q2 2026.